How Ketamine Tablets Are Absorbed in the Gut: The Science of GI Absorption

Understanding how ketamine tablets are absorbed through the gastrointestinal (GI) tract is essential for both patients and clinicians. The journey from tablet to bloodstream involves multiple steps, each of which can be influenced by physiological factors, food intake, and the tablet formulation itself. This article breaks down the science behind oral ketamine absorption.

The Journey of a Ketamine Tablet

When you swallow a ketamine tablet, it passes through a series of environments before the drug reaches systemic circulation:

1. The Stomach

The tablet first encounters the acidic environment of the stomach (pH 1.5–3.5). Ketamine hydrochloride, the most common salt form used in tablets, is highly water-soluble and dissolves readily in gastric fluid.

Key points about gastric processing:

• Dissolution begins here — the tablet breaks down into dissolved ketamine molecules
• Gastric emptying rate determines how quickly dissolved ketamine reaches the small intestine, where most absorption occurs
• Stomach pH matters — patients taking proton pump inhibitors (PPIs) or H2 blockers have a higher gastric pH, which may slightly alter dissolution kinetics
• Food in the stomach slows gastric emptying, delaying (but not necessarily reducing) absorption

The stomach itself absorbs relatively little ketamine. Its primary role is dissolution and transit.

2. The Small Intestine

The small intestine is where the majority of ketamine absorption takes place. The duodenum and jejunum provide:

• Enormous surface area — the intestinal villi and microvilli create roughly 250 square meters of absorptive surface
• Favorable pH — the slightly alkaline environment (pH 6–7.4) is well-suited to ketamine absorption
• Rich blood supply — dense capillary networks in the intestinal wall rapidly transport absorbed drug into the portal circulation

Ketamine crosses the intestinal epithelium primarily through passive transcellular diffusion. As a small, lipophilic molecule (molecular weight ~238), ketamine easily passes through the lipid bilayers of intestinal cells. This is in contrast to larger molecules or highly charged compounds that require active transport mechanisms.

3. The Portal Circulation and First-Pass Metabolism

After crossing the intestinal wall, ketamine enters the hepatic portal vein and travels directly to the liver before reaching the general circulation. This is where oral ketamine loses a significant portion of its dose.

The liver's cytochrome P450 enzymes — primarily CYP3A4 and CYP2B6 — rapidly metabolize ketamine to norketamine, its primary active metabolite. This first-pass metabolism is the main reason oral ketamine has a bioavailability of only 20–25%, compared to nearly 100% for intravenous administration.

However, norketamine is not inactive. It retains approximately 30% of ketamine's NMDA receptor blocking activity, and some researchers believe it contributes meaningfully to the therapeutic effects of oral dosing.

Factors That Influence GI Absorption

Gastric Emptying Rate

Anything that speeds or slows gastric emptying will affect how quickly ketamine reaches the absorptive surface of the small intestine:

For practical guidance on food timing, see our article on taking tablets on an empty stomach.

Intestinal Motility

The rate at which material moves through the small intestine affects the contact time between dissolved ketamine and the absorptive surface. Conditions that accelerate transit (diarrhea, inflammatory bowel disease, short bowel syndrome) may reduce total absorption. Conversely, slower transit generally allows more complete absorption.

Intestinal Blood Flow

Blood flow to the intestinal wall determines how quickly absorbed ketamine is carried away from the absorption site and into the portal circulation. Reduced splanchnic blood flow — from heart failure, shock, or certain medications — can decrease absorption rates.

pH and Ionization

Ketamine is a weak base with a pKa of 7.5. In the slightly acidic to neutral pH of the upper small intestine, a portion of ketamine molecules exist in their un-ionized (lipophilic) form, which crosses cell membranes more easily. The Henderson-Hasselbalch equation predicts that at intestinal pH ~6.5, roughly 10% of ketamine is un-ionized — sufficient for substantial passive absorption given the drug's inherent lipophilicity.

CYP450 Enzyme Activity

While not strictly a GI factor, the activity of metabolic enzymes in both the intestinal wall and the liver profoundly affects how much ketamine survives to reach systemic circulation:

• CYP3A4 inducers (carbamazepine, rifampin, St. John's wort) increase ketamine metabolism and reduce bioavailability
• CYP3A4 inhibitors (ketoconazole, grapefruit juice, erythromycin) decrease metabolism and may increase bioavailability
• Genetic polymorphisms — individual variation in CYP2B6 and CYP3A4 activity means some patients are "fast metabolizers" and others are "slow metabolizers"

For more on these interactions, see our drug interactions guide.

The Role of Norketamine

A critical nuance of oral ketamine's GI absorption story is that the extensive first-pass metabolism produces large quantities of norketamine. After oral dosing, the norketamine-to-ketamine ratio in plasma is significantly higher than after IV administration — often 3:1 or greater.

This has clinical implications:

• Norketamine has its own NMDA receptor activity, contributing to both antidepressant and analgesic effects
• Norketamine has a longer half-life (~12 hours vs. ~2.5 hours for ketamine), providing a more sustained pharmacological effect
• Some researchers hypothesize that the higher norketamine levels from oral dosing may partially explain why oral ketamine can be therapeutically effective despite its low parent drug bioavailability

The Norketamine Hypothesis

A 2019 study in Biological Psychiatry demonstrated that norketamine has antidepressant-like effects in animal models independent of its parent compound. If this translates to humans, it suggests oral ketamine's extensive first-pass metabolism may be a feature rather than a bug — producing a sustained-release-like effect through gradual norketamine exposure.

Bioavailability Comparisons

To put oral tablet absorption in context:

For a more detailed breakdown, see our bioavailability guide.

Clinical Implications of GI Absorption Variability

The variable nature of GI absorption means that two patients taking the same oral dose may achieve different blood levels. This is why:

1. Titration is essential — starting low and adjusting based on response accounts for individual absorption differences. See our titration protocols guide.
2. Consistency matters — taking tablets at similar times relative to meals helps reduce day-to-day variability in absorption
3. Monitoring symptoms helps identify whether absorption is adequate. Our guide on monitoring treatment response covers this topic.
4. Formulation changes require attention — switching between compounding pharmacies or formulations may alter absorption characteristics even at the same dose

Ongoing Research

Several areas of active investigation aim to improve oral ketamine's GI absorption:

• Cyclodextrin complexes — molecular encapsulation that may improve solubility and absorption
• Lipid-based formulations — using fatty acid vehicles to enhance lymphatic absorption, partially bypassing first-pass metabolism
• Mucoadhesive polymers — extended-contact formulations that increase intestinal residence time
• Enteric coatings — targeting release to specific intestinal segments with optimal absorption conditions

These approaches could potentially increase oral bioavailability beyond the current 20–25% range, making oral dosing more efficient and predictable.

What This Means for Patients

The practical takeaways from GI absorption science are:

• Take your tablets consistently — same time of day, same relationship to meals
• Be aware of drug interactions that can alter metabolism
• Report GI symptoms (nausea, diarrhea, constipation) to your provider, as they may affect absorption
• Do not assume your dose needs to match what someone else takes — absorption is individual
• Give dose changes time — it may take several days of consistent dosing to assess a new dose level

References

• Pharmacokinetics of Ketamine and Its Major Metabolites — Key pharmacokinetic study establishing oral ketamine bioavailability parameters
• Norketamine as an Active Metabolite: Antidepressant Mechanisms — Research on norketamine's independent antidepressant activity (Biological Psychiatry, 2019)
• First-Pass Metabolism of Ketamine — NIH-indexed review of hepatic metabolism pathways for ketamine
• Gastrointestinal Drug Absorption: Principles and Variability — Comprehensive review of factors affecting oral drug absorption
• CYP450 Pharmacogenomics and Ketamine Metabolism — Study on genetic variation in ketamine metabolizing enzymes